Lacopat Packung Zur Behandlungseinleitung

Lacosamide, the active ingredient in Lacopat Packung Zur Behandlungseinleitung, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacopat Packung Zur Behandlungseinleitung as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication used in the management of seizure disorders.

Partial‑onset seizures (epilepsy): reduces seizure frequency as monotherapy or adjunctive therapy. Adjunctive therapy for refractory focal seizures: added when seizures persist despite other agents. Secondary generalized seizures arising from focal onset: helps prevent progression of seizure activity.

Lacosamide may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Nausea or vomiting - Headache - Fatigue or somnolence - Diplopia (double vision) - Ataxia or unsteady gait

Serious or Rare Side Effects: - Cardiac conduction abnormalities, including PR‑interval prolongation - Suicidal ideation or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including anaphylaxis - Hepatic dysfunction or elevated liver enzymes

When prescribing lacosamide, several safety considerations are important.

Renal impairment: adjust dose in patients with reduced kidney function. Cardiac monitoring: obtain baseline ECG and monitor for PR‑interval changes. Abrupt discontinuation: taper gradually to avoid seizure worsening. Hepatic impairment: use with caution in patients with liver disease. Hypersensitivity: avoid in individuals with known allergy to lacosamide. Store at ambient temperature: keep in original pack, protect from moisture and excessive heat.

Lacosamide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase lacosamide plasma levels. - Co‑administration with other sodium‑channel blockers can heighten risk of cardiac conduction delays. - Drugs that markedly prolong PR interval should not be combined.

Moderate Interactions (Monitor Closely): - Carbamazepine may reduce lacosamide concentrations. - Oral contraceptives may become less effective. - Alcohol can enhance central nervous system depression. - Other antiepileptics may require dose adjustments. - Antihypertensive agents may have additive effects on blood pressure.